Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Project:
Instituto de Salud Carlos III PI016/0503
,
Instituto de Salud Carlos III PI14/0063
,
Instituto de Salud Carlos III PI14/0700
,
Instituto de Salud Carlos III PI17/0420
,
Instituto de Salud Carlos III PI17/0498
,
Instituto de Salud Carlos III PI19/01337
,
Instituto de Salud Carlos III COVID19617
,
Instituto de Salud Carlos III COV20/00070
,
Ministerio de Economía y Competitividad RD16/0025/0006
,
Agencia Estatal de Investigación INT19/00036
,
Agencia Estatal de Investigación INT20/00031
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-250
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-948